Why did ResMed acquire Noctrix Health and its Nidra device for $340M?

ResMed’s $340 million purchase of Noctrix Health adds the FDA De Novo-cleared Nidra neuromodulation therapy for restless legs syndrome to its portfolio. The acquisition expands ResMed’s reach beyond CPAPs into digital and nonpharmacologic sleep therapies, integrating Noctrix’s wearable into its connected ecosystem to diversify revenue and modernize its sleep-tech offerings.